Pembrolizumab approved as standard first-line therapy for head and neck cancer

Written by Louis Gautier, Future Science Group

Keytruda™ (pembrolizumab) has recently been approved for use in Europe for advanced head and neck cancer following a major Phase-III clinical trial led by the Institute of Cancer Research (London, UK). Researchers also showed it was possible to predict which patients would respond well to the immunotherapy. Approximately 12,000 people in the UK are diagnosed with head and neck cancer each year, with around half being diagnosed at Stage III or IV of the disease when the cancer begins to metastasize. Most cases used to be linked to tobacco and alcohol consumption, but the recent rapid increase in cases that...

To view this content, please register now for access

It's completely free